Bone marrow CD14+CD206+ M2-like monocyte-macrophages as a potential complementary biomarker for bone marrow MRD in high-risk neuroblastoma
- 1Department of Clinical Laboratory, Tianjin Union Medical Center, Nankai University
- 2Department of Pediatric Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer
- 3School of Medical Laboratory, Tianjin Medical University
Abstract
Neuroblastoma (NB) is a highly aggressive pediatric malignancy, frequently associated with a substantial risk of bone marrow metastasis and recurrence. The persistence of minimal residual disease (MRD) remains the primary obstacle to successful treatment outcomes. Bone marrow minimal residual disease (MRD) assessment in high-risk neuroblastoma primarily relies on the direct detection of residual tumor cells. However, the accompanying immune-microenvironmental changes remain incompletely characterized. In this study, GD2-directed immunocytochemistry, complemented by GD2-based flow cytometry, was used for the reference classification of bone marrow disease status in a cohort of 143 patients with high-risk neuroblastoma. We evaluated a panel of peripheral blood biomarkers, identifying NSE, CRP, FBG, and D-dimer as exhibiting significant differences between MRD-positive and MRD-negative groups; however, these biomarkers demonstrated limited diagnostic utility, with area under the curve (AUC) values below 0.7. Importantly, bone marrow CD14 ⁺ CD206 ⁺ M2-like monocyte-macrophages showed discriminatory ability for GD2-defined bone marrow MRD status (AUC = 0.794), with an optimal threshold of 1.71×10 ⁴ /mL. Additionally, the proportion of CD14 ⁺ CD206 ⁺ macrophages showed a positive correlation with GD2 positivity in bone marrow samples. These findings suggest that bone marrow CD14 ⁺ CD206 ⁺ M2-like monocyte-macrophages showed potential as an auxiliary immune biomarker associated with bone marrow MRD status in high-risk NB. These findings require validation in larger, independent cohorts.
Related
- Complementary cytotoxicity of GD2-targeted photoimmunotherapy and 5-aminolevulinic acid photodynamic therapy in neuroblastoma and osteosarcoma
- Inhibition of VEGFR1 Tyrosine Kinase Signaling Attenuates Development of Lung Emphysema by Recruiting Monocyte-derived Macrophages
- Integrative Multi-Omics and Single-Cell Analyses Identify FKBP10 as a CAF-Associated Biomarker Linked to ECM Remodeling and Aggressiveness in Neuroblastoma
- Inhibitory Nectin-2/TIGIT interactions between CD163+ macrophages and CD8+ T cells in spatially defined immune niches associate with poor outcomes in neuroblastoma
- FcγR-mediated antibody-dependent enhancement of SARS-CoV-2 infection in human monocyte-derived macrophages
BibTeX
@article{hu2026bone,
title = {{Bone marrow CD14+CD206+ M2-like monocyte-macrophages as a potential complementary biomarker for bone marrow MRD in high-risk neuroblastoma}},
author = {Xiaoyan Hu and Lin Liu and Yuge Ni and Chen Huang and Yan Jin and Baocheng Gong and Tiantian She and Chong Chen},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1904750},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1904750/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Bone marrow CD14+CD206+ M2-like monocyte-macrophages as a potential complementary biomarker for bone marrow MRD in high-risk neuroblastoma
AU - Xiaoyan Hu
AU - Lin Liu
AU - Yuge Ni
AU - Chen Huang
AU - Yan Jin
AU - Baocheng Gong
AU - Tiantian She
AU - Chong Chen
PY - 2026
DA - 2026/10/28
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1904750
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1904750/full
AB - Neuroblastoma (NB) is a highly aggressive pediatric malignancy, frequently associated with a substantial risk of bone marrow metastasis and recurrence. The persistence of minimal residual disease (MRD) remains the primary obstacle to successful treatment outcomes. Bone marrow minimal residual disease (MRD) assessment in high-risk neuroblastoma primarily relies on the direct detection of residual tumor cells. However, the accompanying immune-microenvironmental changes remain incompletely characterized. In this study, GD2-directed immunocytochemistry, complemented by GD2-based flow cytometry, was used for the reference classification of bone marrow disease status in a cohort of 143 patients with high-risk neuroblastoma. We evaluated a panel of peripheral blood biomarkers, identifying NSE, CRP, FBG, and D-dimer as exhibiting significant differences between MRD-positive and MRD-negative groups; however, these biomarkers demonstrated limited diagnostic utility, with area under the curve (AUC) values below 0.7. Importantly, bone marrow CD14 ⁺ CD206 ⁺ M2-like monocyte-macrophages showed discriminatory ability for GD2-defined bone marrow MRD status (AUC = 0.794), with an optimal threshold of 1.71×10 ⁴ /mL. Additionally, the proportion of CD14 ⁺ CD206 ⁺ macrophages showed a positive correlation with GD2 positivity in bone marrow samples. These findings suggest that bone marrow CD14 ⁺ CD206 ⁺ M2-like monocyte-macrophages showed potential as an auxiliary immune biomarker associated with bone marrow MRD status in high-risk NB. These findings require validation in larger, independent cohorts.
SN - 2234-943X
ER -